Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
David Wojciechowski, Flavio VincentiKidney Transplant Service, University of California, San Francisco, CA, USAAbstract: In June 2011, the US Food and Drug Administration approved belatacept for the prophylaxis of organ rejection in adult kidney transplant recipients. This review discusses the use o...
Saved in:
Main Authors: | Wojciechowski D, Vincenti F |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/abfcf8c1a4c946dba0610b7dfa88f69c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
by: Ippoliti G, et al.
Published: (2012) -
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
by: Florian Terrec, et al.
Published: (2021) -
Characterizing pre-transplant and post-transplant kidney rejection risk by B cell immune repertoire sequencing
by: Silvia Pineda, et al.
Published: (2019) -
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
by: Junichiro Sageshima, et al.
Published: (2009) -
A comparison between the effect of oral and intravenous Prednisolone in prevention of acute rejection during the first two weeks of renal transplantation
by: F Oliaei, et al.
Published: (2005)